We started Genesis Therapeutics in 2019 with origins in field-leading AI + biophysics research. Since then, we’ve dramatically accelerated innovation in Machine Learning and molecular simulation technologies for drug discovery, with the goal of providing new treatments for patients with severe diseases.
We are a mission-driven group of researchers, engineers, and drug developers. We believe close-knit, interdisciplinary collaboration is crucial for inventing important new technology and rapidly advancing optimal therapies.
To advance our mission, we are looking for an eager Talent & Place Coordinator to ensure all support activities are carried out efficiently and effectively. The ideal candidate will be versed in daily support operations, recruiting & scheduling coordination, able to autonomously plan the most efficient administrative procedures, and will be able to proactively discover new ways to do the job more efficiently. This will require excellent communication and organizational skills. Given the office management responsibilities of this position, ideally you must be able to work on-site day-to-day, with occasional flexibility to work from home as needed.
If you thrive in a fast-paced, innovative and collaborative startup environment, we encourage you to apply and explore the opportunity with us.
About Genesis Therapeutics
Genesis Therapeutics is a pioneering AI Biotech company focusing on the discovery of novel drugs using unique approaches to both undrugged and underdeveloped targets with the goal of providing new treatments for patients with severe diseases.
Genesis has raised over
$280M in funding from top technology and biotech investors, including Andreessen Horowitz, Rock Springs Capital, T. Rowe Price, Fidelity, Radical Ventures, NVentures (NVIDIA's VC arm), BlackRock, and Menlo Ventures. In addition, Genesis has announced two AI platform collaborations across a range of therapeutic areas with
Genentech and h
Eli Lilly, the latter of which entailed a $20M upfront payment with a $670M total deal size. We’ve also been featured in
Forbes 30u30 and in
Forbes AI 50.
Genesis originated in
graph machine learning research in Vijay Pande’s lab at Stanford, when it was joined by legendary drug hunters and biotech entrepreneurs (including Dr. Leonard Bell, founder and CEO of Alexion Pharmaceuticals, acquired by Astra Zeneca for $39Bn; and Peppi Prasit, storied chemist from Merck known for Vioxx, Arcoxia, Singulair, who then went on to found Amira Pharmaceuticals, acquired by BMS, and Inception Sciences). The company is making strong progress in expanding the domain of our AI technology with the advance of our pipeline of best-in-class and first-in-class programs, both internal targets and those in partnership with Genentech and Lilly.